Login to Your Account

Other News To Note

Thursday, July 5, 2012
• Celtic Pharmaceutical Holdings LP, of London, reported Phase I/II data showing that Xerecept (corticorelin acetate) is safe and can reduce or eliminate the need for steroids in pediatric patients with cerebral tumors, thus reducing or eliminating steroid-associated side effects.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription